Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Cost of Revenue: 2018-2025

Historic Cost of Revenue for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to $6.3 million.

  • Sunshine Biopharma's Cost of Revenue rose 13.91% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 9.60%. This contributed to the annual value of $24.2 million for FY2024, which is 53.64% up from last year.
  • Per Sunshine Biopharma's latest filing, its Cost of Revenue stood at $6.3 million for Q3 2025, which was up 5.95% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cost of Revenue registered a high of $6.9 million during Q2 2024, and its lowest value of $18,515 during Q2 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $5.6 million (2024), whereas its average is $5.3 million.
  • In the last 5 years, Sunshine Biopharma's Cost of Revenue surged by 4,015.10% in 2023 and then fell by 13.81% in 2025.
  • Sunshine Biopharma's Cost of Revenue (Quarterly) stood at $61,289 in 2021, then soared by 3,568.92% to $2.2 million in 2022, then surged by 127.34% to $5.1 million in 2023, then grew by 27.19% to $6.5 million in 2024, then increased by 13.91% to $6.3 million in 2025.
  • Its Cost of Revenue stands at $6.3 million for Q3 2025, versus $6.0 million for Q2 2025 and $6.2 million for Q1 2025.